{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:06:02Z","timestamp":1784549162546,"version":"3.55.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007075","name":"European Society for Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.esmoop.2026.108302","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T19:11:29Z","timestamp":1783365089000},"page":"108302","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world prognostic assessment of the HERO score in metastatic urothelial carcinoma treated with enfortumab vedotin (ARON-2EV study)"],"prefix":"10.1016","volume":"11","author":[{"given":"G.","family":"Roviello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7321-0950","authenticated-orcid":false,"given":"F.","family":"Ciccimarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Urabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Melichar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2105-9258","authenticated-orcid":false,"given":"H.","family":"Studentova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Niedersuess-Beke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0316-9621","authenticated-orcid":false,"given":"T.","family":"B\u00fcttner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1844-8474","authenticated-orcid":false,"given":"A.","family":"G\u00f3mez de Lia\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8453-2474","authenticated-orcid":false,"given":"A.","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3479-4203","authenticated-orcid":false,"given":"Z.W.","family":"Myint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8106-9741","authenticated-orcid":false,"given":"R.M.","family":"Kopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Zgura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4719-053X","authenticated-orcid":false,"given":"A.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1463-8887","authenticated-orcid":false,"given":"M.","family":"Angel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Tural","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Kanesvaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"\u00dcr\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4616-0598","authenticated-orcid":false,"given":"J.","family":"Molina-Cerrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.S.","family":"Marques Monteiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6476-6871","authenticated-orcid":false,"given":"F.","family":"Massari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4096-7385","authenticated-orcid":false,"given":"O.","family":"Fiala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Santoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Antonuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.esmoop.2026.108302_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"10.1016\/j.esmoop.2026.108302_bib2","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41585-024-00872-0","article-title":"The evolving treatment landscape of metastatic urothelial cancer","volume":"21","author":"Roviello","year":"2024","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.esmoop.2026.108302_bib3","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.108302_bib4","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2026.108302_bib5","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.esmoop.2026.108302_bib6","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108302_bib7","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094-2","article-title":"Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial","volume":"22","author":"Yu","year":"2021","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2026.108302_bib8","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.esmoop.2026.108302_bib9","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1200\/JCO.1999.17.10.3173","article-title":"Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy","volume":"17","author":"Bajorin","year":"1999","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2026.108302_bib10","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1200\/JCO.2009.25.4599","article-title":"Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens","volume":"28","author":"Bellmunt","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108302_bib11","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211019642","article-title":"Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study)","volume":"13","author":"Rebuzzi","year":"2021","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108302_bib12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.tracli.2004.11.005","article-title":"Hypoxia and anemia: effects on tumor biology and treatment resistance","volume":"12","author":"Vaupel","year":"2005","journal-title":"Transfus Clin Biol"},{"key":"10.1016\/j.esmoop.2026.108302_bib13","doi-asserted-by":"crossref","DOI":"10.1177\/17562872251412927","article-title":"Real-world use of enfortumab vedotin in metastatic urothelial carcinoma: efficacy, safety, and risk stratification","volume":"18","author":"Catalano","year":"2026","journal-title":"Ther Adv Urol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108302_bib14","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s11523-024-01099-0","article-title":"Enfortumab vedotin following platinum chemotherapy and avelumab maintenance in patients with metastatic urothelial carcinoma: a retrospective data from the ARON-2EV Study","volume":"19","author":"Fiala","year":"2024","journal-title":"Target Oncol"},{"key":"10.1016\/j.esmoop.2026.108302_bib15","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1\u2014update and clarification: from the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2026.108302_bib17","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/cncr.34057","article-title":"Efficacy of enfortumab vedotin in advanced urothelial cancer: analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study","volume":"128","author":"Koshkin","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2026.108302_bib16","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.euros.2025.10.011","article-title":"Clinical and molecular predictors of response and survival in patients with urothelial carcinoma treated with enfortumab vedotin: a systematic review and meta-analysis","volume":"82","author":"Altenni","year":"2025","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.esmoop.2026.108302_bib18","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/bco2.125","article-title":"FGFR2\/3 genomic alterations and response to enfortumab vedotin in metastatic urothelial carcinoma","volume":"3","author":"Adib","year":"2022","journal-title":"BJUI Compass"},{"key":"10.1016\/j.esmoop.2026.108302_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1161089","article-title":"Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer","volume":"13","author":"Jindal","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.esmoop.2026.108302_bib20","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s10147-025-02709-1","article-title":"Association of body mass index and tumor response in metastatic urothelial carcinoma treated with enfortumab vedotin: data from the ULTRA-Japan consortium","volume":"30","author":"Uchimoto","year":"2025","journal-title":"Int J Clin Oncol"},{"issue":"24","key":"10.1016\/j.esmoop.2026.108302_bib21","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer","volume":"393","author":"Powles","year":"2025","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.esmoop.2026.108302_bib23","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1056\/NEJMoa2511674","article-title":"Perioperative enfortumab vedotin and pembrolizumab in bladder cancer","volume":"394","author":"Vulsteke","year":"2026","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.esmoop.2026.108302_bib22","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"Suppl 7","key":"10.1016\/j.esmoop.2026.108302_bib24","article-title":"Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin: Randomized, open-label, phase 3 KEYNOTE-B15 study","volume":"44","author":"Galsky","year":"2026","journal-title":"J Clin Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926022441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926022441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:21:27Z","timestamp":1784546487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926022441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2059702926022441"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108302","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world prognostic assessment of the HERO score in metastatic urothelial carcinoma treated with enfortumab vedotin (ARON-2EV study)","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108302","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"108302"}}